In most studies, ER+/HER2+ tumours have a more aggressive phenotype, as indicated by the patients’ poor prognosis and higher levels of tumour proliferation than those that do not demonstrate HER2-overexpression or gene amplification (Dowsett et al. 2001). This evidence concerns the gene ESR1 and neoplasm.